A phase 1 study of bremelanotide in premenopausal volunteers
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Bremelanotide (Primary)
- Indications Female sexual dysfunction
- Focus Adverse reactions
- 02 May 2022 Data from two phase 1 studies this and other study assessing effects of bremelanotide's agonism at MC4R on caloric intake and body weight, published in the Diabetes, Obesity and Metabolism
- 16 May 2019 New trial record
- 09 May 2019 According to a Palatin Technologies media release, the US FDA requested this phase 1 study. The data from this tudy has been submitted to the FDA.